SCHEMBL761380

SCHEMBL761380

CN1CCCS1(=O)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL178424 0.92
SCHEMBL12243190 0.89 CA1 (0.32)
SCHEMBL13545949 0.78
SCHEMBL10096746 0.72
SCHEMBL20124836 0.72
SCHEMBL28557014 0.69
SCHEMBL762827 0.69 PER2 (0.34)
SCHEMBL12010069 0.69
SCHEMBL13154123 0.69 PER2 (0.31)
SCHEMBL18025292 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 479 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4393916-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2024-07-03 EP disclosed
WO-2024137607-A1 THIADIAZOLE DERIVATIVES AS INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2024-06-27 WO disclosed
WO-2024108198-A2 METHODS OF TREATING OBESITY WITH AN MC4R AGONIST RHYTHM PHARMACEUTICALS, INC. (US) 2024-05-23 WO disclosed
EP-3947392-B1 ISOTHIAZOLIDINE 1,1-DIOXIDE AND 1,4-BUTAN SULTONE CONTAINING RAPAMYCIN DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2024-02-28 EP disclosed
WO-2023245123-A2 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2023-12-21 WO disclosed
US-20230357242-A1 COMPOUND AS AKT KINASE INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-11-09 US disclosed
US-20230357239-A1 PYRIDO[2,3-D]PYRIMIDIN-4-AMINES AS SOS1 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2023-11-09 US disclosed
US-20230357239-A1 PYRIDO[2,3-D]PYRIMIDIN-4-AMINES AS SOS1 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2023-11-09 US disclosed
US-20230348426-A1 OXOPYRROLIDINE FPR2 AGONISTS BRISTOL MYERS SQUIBB CO (US) 2023-11-02 US disclosed
US-20230348426-A1 OXOPYRROLIDINE FPR2 AGONISTS BRISTOL MYERS SQUIBB CO (US) 2023-11-02 US disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 US disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 US disclosed
US-20070043064-A1 7-Substituted 3-nitro-pyrazo[1,5-a] pyrimidines FERRER INTERNACIONAL S.A. (ES) 2007-02-22 US disclosed
US-20070037813-A1 Serine Protease Inhibitors GENENTECH, INC. (US) 2007-02-15 US disclosed
US-20070037813-A1 Serine Protease Inhibitors GENENTECH, INC. (US) 2007-02-15 US disclosed
US-20070032497-A1 Fused-ring compounds and use thereof as drugs JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032497-A1 Fused-ring compounds and use thereof as drugs JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20060135764-A1 Indazole-carboxamide compounds THERAVANCE, INC. 2006-06-22 US disclosed